Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06562348

The ctDNA-RECIST Trial Part One (ctDNA-RECIST)

ctDNA Guided Palliative Systemic Therapy Compared to Standard Care in Metastatic Cancer - The Randomized ctDNA-RECIST Trial

Sponsor: Karen-Lise Garm Spindler

Conditions Gastrointestinal Neoplasm

Interventions Standard of care ctDNA-RECIST guided palliative systemic treatment

Updated 3 times since 2024 Last updated: Apr 29, 2025 Started: Jan 15, 2025 Primary completion: Sep 1, 2029 Completion: Sep 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastrointestinal Neoplasm, this trial is actively recruiting participants. The trial is conducted by Karen-Lise Garm Spindler and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2
Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Karen-Lise Garm Spindler
Vejle Hospital

Data source: Aarhus University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus, Denmark
• Vejle, Denmark